10-K/A: Nutriband Inc. Files Amendment No. 1 to Form 10-K for Fiscal Year Ended January 31, 2025
10-K/A Filing
Nutriband Inc. has filed an amendment to its annual report on Form 10-K for the fiscal year ended January 31, 2025, with updated exhibits and certifications.
Summary
- Nutriband Inc. filed Amendment No. 1 to its Form 10-K for the fiscal year ended January 31, 2025.
- The filing includes exhibits such as the executive clawback policy, certifications from the CEO and CFO, and interactive data files.
- The aggregate market value of voting and non-voting common equity held by non-affiliates was $44,975,804 as of July 31, 2024.
- As of May 13, 2025, the company had 11,154,171 shares of common stock outstanding.
Sentiment
Score: 7
Explanation: The document is a standard regulatory filing, indicating compliance and transparency. The sentiment is neutral to slightly positive due to the certifications provided by the CEO and CFO.
Positives
- The CEO and CFO have certified the accuracy and compliance of the financial report.
- The company has an executive clawback policy in place to recover erroneously awarded compensation.
Management Comments
- Gareth Sheridan, CEO, and Gerald Goodman, CFO, certified the accuracy and compliance of the Form 10-K/A.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Clawback Policy | The company has a clawback policy in place to recover erroneously awarded compensation from executive officers in the event of an accounting restatement. | October 3, 2023 | Aims to improve the quality and reliability of financial reporting and hold executives accountable. |
Stakeholder Impact
- Shareholders are impacted by the accuracy and compliance of financial reporting.
- Executive officers are subject to the clawback policy, which may affect their compensation.
Key Dates
| Date | Description |
|---|---|
| October 3, 2023 | Effective date of the Executive Clawback Policy |
| July 31, 2024 | Date for aggregate market value of voting and non-voting common equity held by non-affiliates: $44,975,804 |
| January 31, 2025 | Fiscal year end date |
| February 4, 2025 | Amendment No. 1 date to the Commercial Development and Clinical Supply Agreement, by and between Kindeva Drug Delivery L.P. and 4P Therapeutics, LLC |
| May 13, 2025 | Date of filing and date company had 11,154,171 shares of common stock outstanding |
Keywords
Form 10-K, Nutriband, Annual Report, Financial Reporting, Clawback Policy, Securities, Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.